The use of α-conotoxin ImI to actualize the targeted delivery of paclitaxel micelles to α7 nAChR-overexpressing breast cancer

Biomaterials

Volumn 42, Issue , 2015, Pages 52-65

  Mei, Dong ^a   Lin, Zhiqiang ^a   Fu, Jijun ^a   He, Bing ^a   Gao, Wei ^a   Ma, Ling ^a   Dai, Wenbing ^a   Zhang, Hua ^a   Wang, Xueqing ^a   Wang, Jiancheng ^a   Zhang, Xuan ^a   Lu, Wanliang ^a   Zhou, Demin ^a   Zhang, Qiang ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Breast cancer; Paclitaxel; PEG DSPE micelles; Targeted delivery; Conotoxin ImI; 7 nAChR

Indexed keywords

BLOOD; CELL DEATH; CONTROLLED DRUG DELIVERY; DISEASES; FLUORESCENCE IMAGING; IMAGING TECHNIQUES; LIGANDS; MAMMALS; MICELLES; SULFUR COMPOUNDS; TUMORS;

BREAST CANCER; CONOTOXINS; PACLITAXEL; PEG-DSPE; TARGETED DELIVERY;

TARGETED DRUG DELIVERY;

ALPHA CONOTOXIN IMI; BUNGAROTOXIN RECEPTOR; CONOTOXIN; NANOCARRIER; PACLITAXEL; UNCLASSIFIED DRUG; ALPHA-CONOTOXIN IMI; CALCIUM; MACROGOL DERIVATIVE; MICELLE; PHOSPHATIDYLETHANOLAMINE; POLYETHYLENE GLYCOL-DISTEAROYLPHOSPHATIDYLETHANOLAMINE;

ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; APOPTOSIS ASSAY; ARTICLE; BINDING AFFINITY; BREAST CANCER; CANCER INHIBITION; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MCF 7 CELL LINE; MICELLE; MOUSE; NONHUMAN; PHYSICAL CHEMISTRY; POLYMERIZATION; PROTEIN EXPRESSION; ANIMAL; BREAST NEOPLASMS; CHEMISTRY; COMPUTER SYSTEM; DRUG EFFECTS; DRUG SCREENING; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; MASS SPECTROMETRY; METABOLISM; NANOMEDICINE; NUDE MOUSE; PATHOLOGY; SYNTHESIS; TOXICITY TESTING; TREATMENT OUTCOME; TUMOR CELL LINE;

MUS;

ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR; ANIMALS; APOPTOSIS; BREAST NEOPLASMS; CALCIUM; CELL LINE, TUMOR; COMPUTER SYSTEMS; CONOTOXINS; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MICE, NUDE; MICELLES; NANOMEDICINE; PACLITAXEL; PHOSPHATIDYLETHANOLAMINES; POLYETHYLENE GLYCOLS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TOXICITY TESTS; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84919632590     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.11.044     Document Type: Article

References (52)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
2. Danhier F., Feron O., Preat V. To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. JControl Release 2010, 148:135-146.
3. Byrne J.D., Betancourt T., Brannon-Peppas L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev 2008, 60:1615-1626.
4. Kedar U., Phutane P., Shidhaye S., Kadam V. Advances in polymeric micelles for drug delivery and tumor targeting. Nanomedicine 2010, 6:714-729.
5. Tong S.W., Xiang B., Dong D.W., Qi X.R. Enhanced antitumor efficacy and decreased toxicity by self-associated docetaxel in phospholipid-based micelles. Int J Pharm 2012, 434:413-419.
6. Wu H., Zhu L., Torchilin V.P. pH-sensitive poly(histidine)-PEG/DSPE-PEG co-polymer micelles for cytosolic drug delivery. Biomaterials 2013, 34:1213-1222.
7. Cesur H., Rubinstein I., Pai A., Onyuksel H. Self-associated indisulam in phospholipid-based nanomicelles: a potential nanomedicine for cancer. Nanomedicine 2009, 5:178-183.
8. Erogbogbo F., Chang C.W., May J., Prasad P.N., Swihart M.T. Energy transfer from a dye donor to enhance the luminescence of silicon quantum dots. Nanoscale 2012, 4:5163-5168.
9. Xiao Y., Hong H., Javadi A., Engle J.W., Xu W., Yang Y., et al. Multifunctional unimolecular micelles for cancer-targeted drug delivery and positron emission tomography imaging. Biomaterials 2012, 33:3071-3082.
10. Du W., Fan Y., Zheng N., He B., Yuan L., Zhang H., et al. Transferrin receptor specific nanocarriers conjugated with functional 7peptide for oral drug delivery. Biomaterials 2013, 34:794-806.
11. Liu S.Q., Wiradharma N., Gao S.J., Tong Y.W., Yang Y.Y. Bio-functional micelles self-assembled from a folate-conjugated block copolymer for targeted intracellular delivery of anticancer drugs. Biomaterials 2007, 28:1423-1433.
12. Acharya S., Dilnawaz F., Sahoo S.K. Targeted epidermal growth factor receptor nanoparticle bioconjugates for breast cancer therapy. Biomaterials 2009, 30:5737-5750.
13. Arcangeli A., Crociani O., Lastraioli E., Masi A., Pillozzi S., Becchetti A. Targeting ion channels in cancer: a novel frontier in antineoplastic therapy. Curr Med Chem 2009, 16:66-93.
14. DeBin J.A., Maggio J.E., Strichartz G.R. Purification and characterization of chlorotoxin, a chloride channel ligand from the venom of the scorpion. Am J Physiol 1993, 264:C361-C369.
15. Deshane J., Garner C.C., Sontheimer H. Chlorotoxin inhibits glioma cell invasion via matrix metalloproteinase-2. JBiol Chem 2003, 278:4135-4144.
16. Kievit F.M., Veiseh O., Fang C., Bhattarai N., Lee D., Ellenbogen R.G., et al. Chlorotoxin labeled magnetic nanovectors for targeted gene delivery to glioma. ACS Nano 2010, 4:4587-4594.
17. Xiang Y., Liang L., Wang X., Wang J., Zhang X., Zhang Q. Chloride channel-mediated brain glioma targeting of chlorotoxin-modified doxorubicine-loaded liposomes. JControl Release 2011, 152:402-410.
18. Qin C., He B., Dai W., Zhang H., Wang X., Wang J., et al. Inhibition of metastatic tumor growth and metastasis via targeting metastatic breast cancer by chlorotoxin-modified liposomes. Mol Pharm 2014, 11:3233-3241.
19. Egleton R.D., Brown K.C., Dasgupta P. Nicotinic acetylcholine receptors in cancer: multiple roles in proliferation and inhibition of apoptosis. Trends Pharmacol Sci 2008, 29:151-158.
20. Jones A.K., Buckingham S.D., Sattelle D.B. Proteins interacting with nicotinic acetylcholine receptors: expanding functional and therapeutic horizons. Trends Pharmacol Sci 2010, 31:455-462.
21. Paleari L., Cesario A., Fini M., Russo P. alpha7-Nicotinic receptor antagonists at the beginning of a clinical era for NSCLC and mesothelioma?. Drug Discov Today 2009, 14:822-836.
22. Paleari L., Negri E., Catassi A., Cilli M., Servent D., D'Angelillo R., et al. Inhibition of nonneuronal alpha7-nicotinic receptor for lung cancer treatment. Am J Respir Crit Care Med 2009, 179:1141-1150.
23. Catassi A., Paleari L., Servent D., Sessa F., Dominioni L., Ognio E., et al. Targeting alpha7-nicotinic receptor for the treatment of pleural mesothelioma. Eur J Cancer 2008, 44:2296-2311.
24. Zhan C., Li B., Hu L., Wei X., Feng L., Fu W., et al. Micelle-based brain-targeted drug delivery enabled by a nicotine acetylcholine receptor ligand. Angew Chem Int Ed Engl 2011, 50:5482-5485.
25. Chen C.S., Lee C.H., Hsieh C.D., Ho C.T., Pan M.H., Huang C.S., et al. Nicotine-induced human breast cancer cell proliferation attenuated by garcinol through down-regulation of the nicotinic receptor and cyclin D3 proteins. Breast Cancer Res Treat 2011, 125:73-87.
26. Lin W., Hirata N., Sekino Y., Kanda Y. Role of alpha7-nicotinic acetylcholine receptor in normal and cancer stem cells. Curr Drug Targets 2012, 13:656-665.
27. Whiteaker P., Christensen S., Yoshikami D., Dowell C., Watkins M., Gulyas J., et al. Discovery, synthesis, and structure activity of a highly selective alpha7 nicotinic acetylcholine receptor antagonist. Biochemistry-US 2007, 46:6628-6638.
28. Lewis R.J. Conotoxin venom peptide therapeutics. Adv Exp Med Biol 2009, 655:44-48.
29. Livett B.G., Gayler K.R., Khalil Z. Drugs from the sea: conopeptides as potential therapeutics. Curr Med Chem 2004, 11:1715-1723.
30. Lewis R.J., Garcia M.L. Therapeutic potential of venom peptides. Nat Rev Drug Discov 2003, 2:790-802.
31. Klimis H., Adams D.J., Callaghan B., Nevin S., Alewood P.F., Vaughan C.W., et al. Anovel mechanism of inhibition of high-voltage activated calcium channels by alpha-conotoxins contributes to relief of nerve injury-induced neuropathic pain. Pain 2011, 152:259-266.
32. Aina O.H., Sroka T.C., Chen M.L., Lam K.S. Therapeutic cancer targeting peptides. Biopolymers 2002, 66:184-199.
33. McIntosh J.M., Yoshikami D., Mahe E., Nielsen D.B., Rivier J.E., Gray W.R., et al. Anicotinic acetylcholine receptor ligand of unique specificity, alpha-conotoxin ImI. JBiol Chem 1994, 269:16733-16739.
34. Johnson D.S., Martinez J., Elgoyhen A.B., Heinemann S.F., McIntosh J.M. alpha-Conotoxin ImI exhibits subtype-specific nicotinic acetylcholine receptor blockade: preferential inhibition of homomeric alpha 7 and alpha 9 receptors. Mol Pharmacol 1995, 48:194-199.
35. Cai D., Gao W., He B., Dai W., Zhang H., Wang X., et al. Hydrophobic penetrating peptide PFVYLI-modified stealth liposomes for doxorubicin delivery in breast cancer therapy. Biomaterials 2014, 35:2283-2294.
36. Yu C., He B., Xiong M.H., Zhang H., Yuan L., Ma L., et al. The effect of hydrophilic and hydrophobic structure of amphiphilic polymeric micelles on their transport in epithelial MDCK cells. Biomaterials 2013, 34:6284-6298.
37. He C., Hu Y., Yin L., Tang C., Yin C. Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials 2010, 31:3657-3666.
38. Mei H., Shi W., Pang Z., Wang H., Lu W., Jiang X., et al. EGFP-EGF1 protein-conjugated PEG-PLA nanoparticles for tissue factor targeted drug delivery. Biomaterials 2010, 31:5619-5626.
39. Lee J., Lee S.C., Acharya G., Chang C.J., Park K. Hydrotropic solubilization of paclitaxel: analysis of chemical structures for hydrotropic property. Pharm Res 2003, 20:1022-1030.
40. Cho Y.W., Lee J., Lee S.C., Huh K.M., Park K. Hydrotropic agents for study of invitro paclitaxel release from polymeric micelles. JControl Release 2004, 97:249-257.
41. Huo M., Zou A., Yao C., Zhang Y., Zhou J., Wang J., et al. Somatostatin receptor-mediated tumor-targeting drug delivery using octreotide-PEG-deoxycholic acid conjugate-modified N-deoxycholic acid-O, N-hydroxyethylation chitosan micelles. Biomaterials 2012, 33:6393-6407.
42. Hirata N., Sekino Y., Kanda Y. Nicotine increases cancer stem cell population in MCF-7 cells. Biochem Biophys Res Commun 2010, 403:138-143.
43. Wu C.H., Lee C.H., Ho Y.S. Nicotinic acetylcholine receptor-based blockade: applications of molecular targets for cancer therapy. Clin Cancer Res 2011, 17:3533-3541.
44. Linnoila R.I. From nicotine to breast cancer, implications of cholinergic receptor pathway. JNatl Cancer Inst 2010, 102:1298-1299.
45. Lee C.H., Huang C.S., Chen C.S., Tu S.H., Wang Y.J., Chang Y.J., et al. Overexpression and activation of the alpha9-nicotinic receptor during tumorigenesis in human breast epithelial cells. JNatl Cancer Inst 2010, 102:1322-1335.
46. Arredondo J., Nguyen V.T., Chernyavsky A.I., Bercovich D., Orr-Urtreger A., Kummer W., et al. Central role of alpha7 nicotinic receptor in differentiation of the stratified squamous epithelium. JCell Biol 2002, 159:325-336.
47. Zia S., Ndoye A., Lee T.X., Webber R.J., Grando S.A. Receptor-mediated inhibition of keratinocyte migration by nicotine involves modulations of calcium influx and intracellular concentration. JPharmacol Exp Ther 2000, 293:973-981.
48. 2+ transient generation in IMR-32 neuroblastoma cells. Neurochem Int 2010, 57:269-277.
49. Lopez M.G., Montiel C., Herrero C.J., Garcia-Palomero E., Mayorgas I., Hernandez-Guijo J.M., et al. Unmasking the functions of the chromaffin cell alpha7 nicotinic receptor by using short pulses of acetylcholine and selective blockers. Proc Natl Acad Sci U S A 1998, 95:14184-14189.
50. Codignola A., McIntosh J.M., Cattaneo M.G., Vicentini L.M., Clementi F., Sher E. alpha-Conotoxin imperialis I inhibits nicotine-evoked hormone release and cell proliferation in human neuroendocrine carcinoma cells. Neurosci Lett 1996, 206:53-56.
51. Vakifahmetoglu H., Olsson M., Zhivotovsky B. Death through a tragedy: mitotic catastrophe. Cell Death Differ 2008, 15:1153-1162.
52. Zhang Y., Zhang H., Wang X., Wang J., Zhang X., Zhang Q. The eradication of breast cancer and cancer stem cells using octreotide modified paclitaxel active targeting micelles and salinomycin passive targeting micelles. Biomaterials 2012, 33:679-691.